Osimertinib-Related QTc Prolongation: Real-World Incidence and Impact of Drug Dosing on Recurrence Risk

IF 3.3 3区医学 Q2 ONCOLOGY

Clinical lung cancer Pub Date : 2024-07-02 DOI:10.1016/j.cllc.2024.06.012

Olivia H. Chen , Wesley K.Y. Wong , Kevin K.S. Mok , Landon L. Chan , Candy Tang , Molly S.C. Li

引用次数: 0

Abstract

•
In a real-world retrospective study of 970 patients treated with osimertinib, incidence of grade 3 QTc prolongation was 0.9% which was similar to clinical trials. No events of ventricular arrhythmia or arrhythmia-related deaths were observed.
•
Baseline QTc prolongation (QTc ≥450ms) may be a potential risk factor for osimertinib-related grade 3 QTc prolongation.
•
In patients with grade 3 osimertinib-related QTc prolongation, rechallenging osimertinib at 80mg daily dose confers high recurrence risk while dose reduction mitigates recurrence risk.

查看原文本刊更多论文

奥希替尼相关 QTc 延长：现实世界中的发病率以及药物剂量对复发风险的影响

-在一项对970名接受奥希替尼治疗的患者进行的真实世界回顾性研究中，3级QTc延长的发生率为0.9%，与临床试验相似。基线QTc延长（QTc≥450ms）可能是奥希替尼相关3级QTc延长的潜在风险因素。在出现奥希替尼相关3级QTc延长的患者中，以每日80毫克的剂量再接受奥希替尼治疗具有较高的复发风险，而减少剂量可降低复发风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical lung cancer 医学-肿瘤学

CiteScore

7.00

自引率

2.80%

发文量

159

审稿时长

24 days

期刊介绍： Clinical Lung Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of lung cancer. Clinical Lung Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of lung cancer. The main emphasis is on recent scientific developments in all areas related to lung cancer. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.